ATI-50002
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia
Trial Timeline
Mar 22, 2018 → Oct 30, 2019
NCT ID
NCT03495817About ATI-50002
ATI-50002 is a phase 2 stage product being developed by Aclaris Therapeutics for Androgenetic Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT03495817. Target conditions include Androgenetic Alopecia.
What happened to similar drugs?
0 of 7 similar drugs in Androgenetic Alopecia were approved
Approved (0) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03551821 | Phase 2 | Completed |
| NCT03495817 | Phase 2 | Completed |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 23 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 37 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 41 |
| VDPHL01 | Veradermics | Phase 2 | 33 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 41 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 36 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 38 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 34 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 29 |